De‐intensification of basal‐bolus therapy by replacing prandial insulin with once‐weekly subcutaneous semaglutide in individuals with well‐controlled type 2 diabetes: A single‐centre, open‐label randomised trial ( <scp>TRANSITION</scp> ‐ <scp>T2D</sc
In people with type 2 diabetes well controlled (HbA<sub>1c</sub> ≤7.5% [≤58 mmol/mol]) on MDI ≤120 units/day, replacing multiple daily injections of prandial insulin with once-weekly subcutaneous semaglutide can maintain and even improve HbA<sub>1c</sub>, lower body weight and lessen the burden of management.
Authors
- Marcio L. Griebeler
- Jim Bena
- Huijun Xiao (ORCID: https://orcid.org/0000-0001-7536-7526)
- Kimberly Jenkins
- Keren Zhou (ORCID: https://orcid.org/0000-0003-4671-8838)
- Bartolomé Burguera (ORCID: https://orcid.org/0000-0001-9808-8327)
- Kevin M. Pantalone (ORCID: https://orcid.org/0000-0002-3897-4551)
- Nikki Breslaw
- Paloma Rodriguez
- Diana Isaacs
Institutions
- Cleveland Clinic (US)
- Cleveland Clinic Lerner College of Medicine (US)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2024-11-12
- DOI
- https://doi.org/10.1111/dom.16057
- Citations
- 3
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.07
Funders
- Cleveland Clinic